403 related articles for article (PubMed ID: 12399676)
41. Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year.
Van Leent EJ; De Vries HJ; Ebelin ME; Burtin P; Scott G; Bos JD
J Dermatolog Treat; 2007; 18(1):19-22. PubMed ID: 17365262
[TBL] [Abstract][Full Text] [Related]
42. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis.
Eichenfield LF; Beck L
J Allergy Clin Immunol; 2003 May; 111(5):1153-68. PubMed ID: 12743593
[TBL] [Abstract][Full Text] [Related]
43. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
[TBL] [Abstract][Full Text] [Related]
44. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
[TBL] [Abstract][Full Text] [Related]
45. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases.
Hebert AA; Warken KA; Cherill R
Semin Cutan Med Surg; 2001 Dec; 20(4):260-7. PubMed ID: 11770913
[TBL] [Abstract][Full Text] [Related]
46. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis.
Aschoff R; Schwanebeck U; Bräutigam M; Meurer M
Exp Dermatol; 2009 Jan; 18(1):24-9. PubMed ID: 18637133
[TBL] [Abstract][Full Text] [Related]
47. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.
Staab D; Pariser D; Gottlieb AB; Kaufmann R; Eichenfield LF; Langley RG; Scott G; Ebelin ME; Barilla D; Schmidli H; Burtin P
Pediatr Dermatol; 2005; 22(5):465-71. PubMed ID: 16191004
[TBL] [Abstract][Full Text] [Related]
48. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.
Kempers S; Boguniewicz M; Carter E; Jarratt M; Pariser D; Stewart D; Stiller M; Tschen E; Chon K; Wisseh S; Abrams B
J Am Acad Dermatol; 2004 Oct; 51(4):515-25. PubMed ID: 15389185
[TBL] [Abstract][Full Text] [Related]
49. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age.
Ellis CN; Kahler KH; Grueger J; Chang J
Am J Clin Dermatol; 2006; 7(2):133-9. PubMed ID: 16605293
[TBL] [Abstract][Full Text] [Related]
50. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study.
Cicek D; Kandi B; Bakar S; Turgut D
J Dermatolog Treat; 2009; 20(6):344-9. PubMed ID: 19954391
[TBL] [Abstract][Full Text] [Related]
51. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis.
Luger T; Van Leent EJ; Graeber M; Hedgecock S; Thurston M; Kandra A; Berth-Jones J; Bjerke J; Christophers E; Knop J; Knulst AC; Morren M; Morris A; Reitamo S; Roed-Petersen J; Schoepf E; Thestrup-Pedersen K; Van Der Valk PG; Bos JD
Br J Dermatol; 2001 Apr; 144(4):788-94. PubMed ID: 11298538
[TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of pimecrolimus cream 1% in the daily practice: results of a patient self-observation study in patients with atopic dermatitis.
Luger TA; Gollnick H; Schwennesen T; Bextermöller R; Freytag S; Bräutigam M
J Dtsch Dermatol Ges; 2007 Oct; 5(10):908-14. PubMed ID: 17910673
[TBL] [Abstract][Full Text] [Related]
53. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
[TBL] [Abstract][Full Text] [Related]
54. Study of the Atopic March: Development of Atopic Comorbidities.
Schneider L; Hanifin J; Boguniewicz M; Eichenfield LF; Spergel JM; Dakovic R; Paller AS
Pediatr Dermatol; 2016 Jul; 33(4):388-98. PubMed ID: 27273433
[TBL] [Abstract][Full Text] [Related]
55. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis.
Schwarz T; Kreiselmaier I; Bieber T; Thaci D; Simon JC; Meurer M; Werfel T; Zuberbier T; Luger TA; Wollenberg A; Bräutigam M
J Am Acad Dermatol; 2008 Jul; 59(1):34-40. PubMed ID: 18462835
[TBL] [Abstract][Full Text] [Related]
56. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.
Eichenfield LF; Lucky AW; Boguniewicz M; Langley RG; Cherill R; Marshall K; Bush C; Graeber M
J Am Acad Dermatol; 2002 Apr; 46(4):495-504. PubMed ID: 11907497
[TBL] [Abstract][Full Text] [Related]
57. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Rigopoulos D; Ioannides D; Kalogeromitros D; Gregoriou S; Katsambas A
Br J Dermatol; 2004 Nov; 151(5):1071-5. PubMed ID: 15541087
[TBL] [Abstract][Full Text] [Related]
58. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants.
Kaufmann R; Fölster-Holst R; Höger P; Thaçi D; Löffler H; Staab D; Bräutigam M;
J Allergy Clin Immunol; 2004 Nov; 114(5):1183-8. PubMed ID: 15536429
[TBL] [Abstract][Full Text] [Related]
59. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Chen SL; Yan J; Wang FS
J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
[TBL] [Abstract][Full Text] [Related]
60. Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients.
Oppel T; Pavicic T; Kamann S; Bräutigam M; Wollenberg A
J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1175-80. PubMed ID: 17894701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
